Literature DB >> 1757932

Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases.

J Sany1, J M Anaya, V Lussiez, M Couret, B Combe, J P Daures.   

Abstract

One hundred and ninety-one patients with severe rheumatoid arthritis (RA) were included in a prospective open longterm study of the safety, efficacy and maintenance of methotrexate (MTX) treatment. The mean duration of MTX treatment was 19 +/- 13.2 (3-58) months; the mean weekly dose of MTX was 10.2 +/- 0.2 mg. Analysis of the 191 patients in an intent-to-treat manner showed a significant improvement of all the clinical variables and a decrease of erythrocyte sedimentation rate with a steroid sparing effect. The probability of continuing MTX therapy for up to 2 years was 65% and for up to 5 years was 46%. Adverse effects of MTX occurred in 37.1% of the patients, but only 15.7% discontinued MTX permanently.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1757932

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  19 in total

1.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.

Authors:  O Sander; G Herborn; E Bock; R Rau
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?

Authors:  A A Stenger; P M Houtman; G A Bruyn
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

3.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 4.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

5.  Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis.

Authors:  G Kolarz; F Mayrhofer; P Peichl; E Posch; O Scherak; F Singer; N Thumb; A Wottawa
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

6.  Experience with low-dose methotrexate: toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis.

Authors:  M Nisar; L Carlisle; R Amos
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

7.  Long-term methotrexate in refractory rheumatoid arthritis; concurrent use of prednisone possibly improves drug-survival.

Authors:  P J Kerstens; A M Boerbooms; E P Brummelkamp; L B Van de Putte
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

8.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.

Authors:  Y Yazici; T Sokka; H Kautiainen; C Swearingen; I Kulman; T Pincus
Journal:  Ann Rheum Dis       Date:  2004-06-18       Impact factor: 19.103

Review 9.  Methotrexate in rheumatoid arthritis: a quarter century of development.

Authors:  Michael E Weinblatt
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 10.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.